The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
48hrs -till meeting - decision will be mid July
Https://www.ukri.org/opportunity/cancer-immunotherapy-response-research-platform/
https://markets.ft.com/data/announce/detail?dockey=600-202406250200BIZWIRE_USPRX____20240624_BW074525-1
It’s in the FT .Sold recently at a loss may buy back in
Just read,
Looks fantastic 👌, this will push us right into the frey when it comes to treatment offered, especially on NHS approval.
Sod Transform, that's like kindergarten to this.
Fingers crossed eh, 48 hours till decision
No - Its just a bit more detail on the trial and confirmation that OBD are shortlisted, nothing more than than was in the Half Year really , just more details on OBDs proposal etc. but worth a read
Also never go on avdfn, that looks great 👍
I'll read it soon, quick glance is that saying we got the award?
Sorry mate, I'm not an investor I just happen to invest.
Family man, big family so I come here first, and look in my spare time. I'll have a look later but its looking positive. You have a certain notification or website you go to for best updates? I'm a good researcher, but you seem on it 👌
Morning, its an impressive trial - Did you see the Business Wire - RNS This Morning ? more detail on the trial. Not dates for award stated , but those are explained on the CIRRP Website
https://uk.advfn.com/stock-market/london/oxford-biodynamics-OBD/share-news/Oxford-BioDynamics-part-of-consortium-shortlisted/94094319
Patience like master jedi yoda may just pay dividends
If we win it, and it's Met with a decent amount of fanfare I may push for a 10p average.
See how it goes, what the market says
Says 3 days, but as most things probably won't see anything positive from it to start taking effect for a few weeks although it may be a big enough signal to get things moving in the right direction.
4.5mill first payment will be kind to us now.
But if it reflects sp performance in this period is 50/50
This trial will be almost with almost all the leg work being done by OBD, tests and use of the UK Labs - Obd will be highly involved - there is no trial without 9BD by the looks of it -spend of £4mil in the first year ( if max awarded) I'm asumeomg it will be cost+ reimbursement which will bring in some decent revenue - but that remains to be seen - need to win it first I suppose .. I think though it emphasises what's been going on in the background.. I think there was a lesson learned there and not even mentioned it until H1 .. more importantly is that the trial is imbedded within 2 NHS trusts, data building .. I won't post anymore on it as it's pointless unless it's confirmed , but it's not a year away it's imminent
So was I,I was at 32p till our death date last week.
I bought a chunk at 5.2p as it fell off a cliff expecting a pull back straight away, but as the dust settled its become worth holding out
Dustyslay.
Unfortunately I am much higher than your 12p and I surely wouldn’t be selling at 9p. I believe we will be rewarded by the end of the year if not Q1 25.
Patience will pay dividends.
GLA LTHs
Totally agree, I'm not even remotely thinking the near future,perhaps some news in the fall, winter perhaps some growth but certainly nothing yet.
Tiny inroads to that 9p I'm looking at, now I'm right down on the average 1p North does wonders for my loss count. That 5.2p buy to now 6.3p highlighted that nicely
Guys,
This is going to come good but not as quick as we expected.When the share price took off late Sept early Oct it took everyone by surprise including the BOD.
PSE just needs a bit of traction and the momentum will happen.I’m up to my neck in this investment so it is in my interest for it to happen but happy to wait for the reward.GLA LTHs
I do recall you bringing this up a while back when dismissing the transform trials as not the end of the world, my head wasn't in it at that point, but I see new refund focus here as after my first buy of shares since last October, I feel in a good position for progress than selling at a loss like it looked the direction.
Only 1 with a developed product you would assume they would jump at it, knowing its there to be fully produce workable results to there studies, than say one that has yet to be at a final stage. Seem strange not to, we could so with a break really.
Heard so much about the trials we missed out on these past few months, that we never got on the list. This should provide a decent footing for us
I did have a feeling that now the damage has been done, and the inevitable crash to 5p on annual financial reports, that all of a sudden we will start seeing influx of events and progress taking place, the company delivering rock bottom prior, than lots of good news to be presented before another sledge hammer.
Like burrow knows his street cred needs restoring, so can't be giving us a flash hope then smash us with the annual after.
So fingers crossed this could be the start
Great, I'll muse over that later tonight.
Be a huge positive first glance
From the webinar
OBD one of only 2 getting to the final interview this week and the only one with a developed product
Cutn paste for sir
In this context, in the UK, the Company recently submitted an application, as part of a public/private partnership involving clinicians and academics from the Universities of Oxford and Birmingham, Imperial NHS Trust, Norfolk and Norwich Universities NHS Trust, and OBD, to UK Research & Innovation's Cancer Immunotherapy Response Research Platform (CIRRP) Grant. The grant is intended to fund development of a broad utility, deep genotyping and phenotyping platform capable of generating insights into patient response, adverse effects, and resistance to immunotherapy, and exemplar project(s) to demonstrate utility. Co-funded by the Office for Life Sciences and the Medical Research Council, a total of £9 million is available over four years.
The consortium's "EpiSwitch CIRRP" application has been shortlisted for interview by an expert panel in late June 2024. If funded, the project would offer UK-based EpiSwitch CiRT and HiRT (Hyper-ICI Response Test) clinical screening, initially to NHS trusts within the consortium, and then to NHS networks across the UK, from OBD's existing ISO15189/UKAS accredited clinical laboratory. It would also create real-world impact data within NHS clinical practice for prediction of ICI response and prognosis of hyperprogressive disease. The project would also seek to advance the understanding of genetic, metabolomic and epigenetic mechanisms behind clinical outcomes, acquired resistance and remission.
FULL DETAILS AND DATES
https://www.ukri.org/opportunity/cancer-immunotherapy-response-research-platform/
What we are looking for tab, and more details are contained lower down within cIRT section of the results
I'm struggling to find the spec!
I think we can count on many inclusions being that of good news, obviously the cirrp has been out longer, but shows that these things take time to build up into many areas.
Where can I locate the details?
As a distraction, what about something that is worth talking about. CIRRP
Final meeting in 3 days time
Has anyone read the spec ?
only downside ? OBD could be too far advanced for the spec. they are funding to investigate a possibile solution across NhS that OBD have already developed and is in use
Project starts in 5 weeks time.
An I the only one who thinks this is potentially great news ?
TBH I never really thought too much into him, only really the narrative from the board.
When the sp performance was outstanding, I'm not sure he correlated that market sentiment to consumer sales and got too far ahead of himself.
Was he lying, which I've found myself saying now, or was it naive exhubberence from an idiot.
The wages seem excessive, and obviously his daughter on marketing with sales not being what was portrayed didn't mark that acquisition in a great light.
But he has done good things, and for a while was ceo of the year!!!
So I just try to move past it now, everything is in place for this to be successful, if the new shares issued is how they say incentives driven then we should expect progress.
But nothing is assured, so we as investors can debate the plan set out and follow it's traction closely in hope this rotten egg, becomes the golden goose we imagined less than a year ago.
When I had a 32p avg, now it's 12p so if it can it could be worth the pain in the end